Hervé Avet‐Loiseau

Research interests

Publications

• Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2204925

• A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

  Blood Advances · 2020 · https://doi.org/10.1182/bloodadvances.2020002827

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0876-z

• Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31240-1

• Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

  Blood · 2018 · https://doi.org/10.1182/blood-2018-03-840132

• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0196-8

• Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

  Haematologica · 2018 · https://doi.org/10.3324/haematol.2018.194118

• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1611750

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

  JAMA Oncology · 2016 · https://doi.org/10.1001/jamaoncol.2016.3160

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-631200

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402551

• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  Nature Communications · 2014 · 10.1038/ncomms3997

• IMWG consensus on risk stratification in multiple myeloma

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.247

• Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1114138

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

  Blood · 2011 · 10.1182/blood-2010-10-299487

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Leukemia · 2010 · https://doi.org/10.1038/leu.2010.60

• Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.27.9158

• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  Leukemia · 2009 · https://doi.org/10.1038/leu.2009.174

• Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

  The Lancet · 2007 · https://doi.org/10.1016/s0140-6736(07)61537-2

• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

  Blood · 2007 · https://doi.org/10.1182/blood-2007-08-107292

• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

  Blood · 2007 · https://doi.org/10.1182/blood-2006-08-040410

• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

  Blood · 2006 · https://doi.org/10.1182/blood-2006-05-022962

• International Staging System for Multiple Myeloma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.04.242

• Genetics and Cytogenetics of Multiple Myeloma

  Cancer Research · 2004 · https://doi.org/10.1158/0008-5472.can-03-2876

Current projects

No projects listed.